These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36542644)

  • 41. Faecal occult blood testing in areas of high incidence and mortality; the effect of screening the population aged 50 to 59.
    Fisher R; Rooney PS
    Colorectal Dis; 2011 Sep; 13(9):1024-9. PubMed ID: 20626761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adenoma detection rates in an opportunistic screening colonoscopy program in Iran, a country with rising colorectal cancer incidence.
    Delavari A; Bishehsari F; Salimzadeh H; Khosravi P; Delavari F; Nasseri-Moghaddam S; Merat S; Ansari R; Vahedi H; Shahbazkhani B; Saberifiroozi M; Sotoudeh M; Malekzadeh R
    BMC Gastroenterol; 2014 Nov; 14():196. PubMed ID: 25404264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Variations in utilisation of colorectal cancer services in South Australia indicated by MBS/PBS benefits: a benefit incidence analysis.
    Lal A; McCaffrey N; Gold L; Roder D; Buckley E
    Aust N Z J Public Health; 2022 Apr; 46(2):237-242. PubMed ID: 35174927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
    de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acceptance on colorectal cancer screening upper age limit in South Korea.
    Luu XQ; Lee K; Lee YY; Suh M; Kim Y; Choi KS
    World J Gastroenterol; 2020 Jul; 26(27):3963-3974. PubMed ID: 32774070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.
    Breekveldt ECH; Lansdorp-Vogelaar I; Toes-Zoutendijk E; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Nagtegaal ID; Krul MF; Kok NFM; Kuhlmann KFD; Vink GR; van Leerdam ME; Elferink MAG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):60-68. PubMed ID: 34822762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of stratifying by family history in colorectal cancer screening programs.
    Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
    Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).
    Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z
    World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term risk of colorectal cancer in individuals with serrated polyps.
    Holme Ø; Bretthauer M; Eide TJ; Løberg EM; Grzyb K; Løberg M; Kalager M; Adami HO; Kjellevold Ø; Hoff G
    Gut; 2015 Jun; 64(6):929-36. PubMed ID: 25399542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality indicators for screening colonoscopy and colonoscopist performance and the subsequent risk of interval colorectal cancer: a systematic review.
    Lund M; Trads M; Njor SH; Erichsen R; Andersen B
    JBI Database System Rev Implement Rep; 2019 Nov; 17(11):2265-2300. PubMed ID: 31188154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial impact of Australia's National Bowel Cancer Screening Program.
    Ananda SS; McLaughlin SJ; Chen F; Hayes IP; Hunter AA; Skinner IJ; Steel MC; Jones IT; Hastie IA; Rieger NA; Shedda S; Compston DJ; Gibbs P
    Med J Aust; 2009 Oct; 191(7):378-81. PubMed ID: 19807627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme.
    Lo SH; Halloran S; Snowball J; Seaman H; Wardle J; von Wagner C
    Gut; 2015 Feb; 64(2):282-91. PubMed ID: 24812001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Small-area geographic and socioeconomic inequalities in colorectal tumour detection in France.
    Fournel I; Bourredjem A; Sauleau EA; Cottet V; Dejardin O; Bouvier AM; Launoy G; Bonithon-Kopp C
    Eur J Cancer Prev; 2016 Jul; 25(4):269-74. PubMed ID: 26067032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of socioeconomic status on stage at presentation, receipt of diagnostic imaging, receipt of treatment and overall survival in colorectal cancer patients.
    Shah R; Chan KKW
    Int J Cancer; 2021 Sep; 149(5):1031-1043. PubMed ID: 33950515
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme.
    Lee TJ; Rutter MD; Blanks RG; Moss SM; Goddard AF; Chilton A; Nickerson C; McNally RJ; Patnick J; Rees CJ
    Gut; 2012 Jul; 61(7):1050-7. PubMed ID: 21940723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ten or More Cumulative Lifetime Adenomas Are Associated with Increased Risk for Advanced Neoplasia and Colorectal Cancer.
    Sullivan BA; Redding TS; Qin X; Gellad ZF; Hauser ER; O'Leary MC; Williams CD; Musselwhite LW; Weiss D; Madison AN; Lieberman D; Provenzale D
    Dig Dis Sci; 2022 Jun; 67(6):2526-2534. PubMed ID: 34089135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.